CYTOMEGALOVIRUS REACTIVATION IN A SINGLE CENTER PAEDIATRIC COHORT UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION AND USE OF LETERMOVIR (EBMT 2026) - Mar 14, 2026 - Abstract #B103; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "The collected variables included: age, donor/recipient CMV serology, prophylaxis with letermovir, myeloablative or reduced-intensity conditioning, administration of serotherapy and donor type (HLA- identical sibling [MSD], haploidentical with post-transplant cyclophosphamide, other related donors [MMFD] and matched unrelated donor [MUD]. CMV reactivation is a common complication following HSCT. Letermovir could be effective for prophylaxis in seropositive paediatric patients without significant toxicity. In our series, patients who received serotherapy reactivated CMV more frequently."
Clinical • Aplastic Anemia • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Gastrointestinal Disorder • Pediatrics • Transplantation
|
|
Marina García-Morin1; María Salvador-Rodríguez1; Teresa Martín Aláez1; Paula Gallardo Ortiz1; Pablo González Navarro2; Eduardo J. Bardón-Cancho1; Elena Cela1; Alba Gonzalez Guerrero1; Jose Manuel Marco-Sanchez1; Cristina Belendez1
|